ImmuneRegen, Hyperion to collaborate on Viprovex testing for treatment of anthrax

By Lisa Kerner

Charlotte, N.C., Aug. 17 - ImmuneRegen BioSciences and Hyperion Biotechnology Inc. will collaborate on additional testing of ImmuneRegen's Viprovex for possible use in the treatment of pulmonary anthrax infection.

The tests will be conducted at Hyperion's research facility located on the U.S. Air Force School of Aerospace Medicine campus in Brooks City-Base, Texas, according to a news release.

Animal studies demonstrated the potential positive effect of Viprovex used both prophylactically and therapeutically to treat the effects of a near lethal anthrax-exposure. Survival rates ranged from 20% to 70% of control animals.

In addition, studies using a formulation of the Viprovex' active ingredient, Homspera, in an animal model of lethal radiation exposure, show increased survival and immune system reconstitution.

Hyperion is a San Antonio biotechnology company focused on biomarker discovery, wound healing, performance enhancement and infectious disease treatment.

Scottsdale, Ariz.-based ImmuneRegen, a wholly owned subsidiary of IR BioSciences Holdings, Inc., is a development-stage biotechnology company specializing in homeland security countermeasures.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.